- Home
- Publications
- Publication Search
- Publication Details
Title
Endothelin-1 and antiangiogenesis
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
Volume 310, Issue 3, Pages R230-R234
Publisher
American Physiological Society
Online
2015-10-29
DOI
10.1152/ajpregu.00373.2015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With SunitinibNovelty and Significance
- (2015) Stephanie Lankhorst et al. HYPERTENSION
- Association Studies Suggest a Key Role for Endothelin-1 in the Pathogenesis of Preeclampsia and the Accompanying Renin–Angiotensin–Aldosterone System SuppressionNovelty and Significance
- (2015) Koen Verdonk et al. HYPERTENSION
- FDA-approved small-molecule kinase inhibitors
- (2015) Peng Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib
- (2014) Stephanie Lankhorst et al. HYPERTENSION
- Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress
- (2013) Stephanie Lankhorst et al. ANTIOXIDANTS & REDOX SIGNALING
- -Arrestin-1 Drives Endothelin-1-Mediated Podocyte Activation and Sustains Renal Injury
- (2013) S. Buelli et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Endothelin as a final common pathway in the pathophysiology of preeclampsia
- (2012) Eric M. George et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Mechanism of hypertension and proteinuria during angiogenesis inhibition
- (2012) Stephanie Lankhorst et al. JOURNAL OF HYPERTENSION
- eNOS Deficiency Acts through Endothelin to Aggravate sFlt-1-Induced Pre-Eclampsia-Like Phenotype
- (2012) F. Li et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Vascular Endothelial Growth Factor (VEGF), VEGF Receptors and Their Inhibitors for Antiangiogenic Tumor Therapy
- (2011) Satoru Takahashi BIOLOGICAL & PHARMACEUTICAL BULLETIN
- The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System
- (2011) Mariëtte H.W. Kappers et al. HYPERTENSION
- Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress
- (2011) Mariëtte H.W. Kappers et al. HYPERTENSION
- Distinct Actions of Endothelin A-Selective Versus Combined Endothelin A/B Receptor Antagonists in Early Diabetic Kidney Disease
- (2011) M. A. Saleh et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- The role of tumour-derived iNOS in tumour progression and angiogenesis
- (2010) V Kostourou et al. BRITISH JOURNAL OF CANCER
- Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
- (2010) Mariëtte H.W. Kappers et al. HYPERTENSION
- Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
- (2009) M. L. Maitland et al. CLINICAL CANCER RESEARCH
- Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
- (2009) Carie S. Facemire et al. HYPERTENSION
- ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats
- (2009) Patricia N Banfor et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- VEGF Inhibition and Renal Thrombotic Microangiopathy
- (2008) Vera Eremina et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started